N/A N=148 Randomized Health Services Research

Nexplanon Application Post-Abortion (NAPA)

Contraception · Abortion, Therapeutic

Bottom Line

View on ClinicalTrials.gov: NCT02037919 ↗

Enrolled (actual)

148

Serious AEs

0.0%

Results posted

Feb 2024

Primary outcome: Primary: Intention-to-treat Analysis of Etonogestrel Implant Use — 40; 19; 3; 3 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Immediate Nexplanon Insertion (Other); Post-op Nexplanon Insertion (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: Female
Sponsor: Family Planning Associates Medical Group, LTD
Primary completion: May 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Intention-to-treat Analysis of Etonogestrel Implant Use	40; 19; 3; 3	—
PRIMARY Per-protocol Analysis of Etonogestrel Implant Use	40; 19; 3; 3; 0; 8	—
SECONDARY Repeat Pregnancy	1; 1; 42; 29	—

Summary

Women who receive Nexplanon immediately post abortion will be significantly more likely to be using the device 6 months after the procedure than those assigned to receive the device 2-4 weeks after the procedure.

Eligibility Criteria

Inclusion Criteria

18 years of age and older,
an intrauterine pregnancy > 14 weeks and <23 6/7 weeks gestation and desire termination of pregnancy
desire a Nexplanon for contraception
able to give informed consent in English
no contraindications to Nexplanon (based on U.S. CDC Medical Eligibility Criteria for Contraception) or D&E

Exclusion Criteria

unable to give informed consent
have any of the following medical conditions: active venous thromboembolism, known or suspected sex-steroid sensitive malignancies, current hepatic disease with abnormal liver function tests, undiagnosed vaginal bleeding, hypersensitivity to any of the ingredients in Nexplanon.
non-surgical management of pregnancy
prior participation in this study
breast cancer or a history of breast cancer

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02037919). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.